ArticleCancer management and research2020
Up-Regulation of circRNA hsa_circ_0003074 Expression is a Reliable Diagnostic and Prognostic Biomarker in Patients with Osteosarcoma.
Article in Cancer management and research, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 1 synthesis or guideline pooled it, 17 citations in OpenAlex.
- Clinicopathologic significance and prognostic value of circRNAs in osteosarcoma: a systematic review and meta-analysis.Journal of orthopaedic surgery and research · 2021Pooled it
- Circular RNAs in osteosarcoma: mechanistic insights, autophagy regulation, and potential therapeutic strategies.Cancer cell international · 2026Review
- Non-Coding RNAs in Diagnostic Pathology of High-Grade Central Osteosarcoma.Diagnostics (Basel, Switzerland) · 2025Review
- Research progress of circRNAs in bone-related diseases.Frontiers in oncology · 2025Review
- Alteration in the Expression of Circular Rnas and its association with the Development and Progression of Osteosarcoma, an Integrative Review with High Sensitivity Research.Asian Pacific journal of cancer prevention : APJCP · 2024Review
- METTL3-mediated m6A modification of circRNF220 modulates miR-330-5p/survivin axis to promote osteosarcoma progression.Journal of cancer research and clinical oncology · 2023Article
- circ‑LRP6 contributes to osteosarcoma progression by regulating the miR‑141‑3p/HDAC4/HMGB1 axis.International journal of oncology · 2022Article
- Circular RNA circ_UBAP2 facilitates the progression of osteosarcoma by regulating microRNA miR-637/high-mobility group box (HMGB) 2 axis.Bioengineered · 2022Article
- Non-coding RNAs as potential biomarkers in osteosarcoma.Frontiers in genetics · 2022Review
- Ginsenoside Rg3 inhibits osteosarcoma progression by reducing circ_0003074 expression in a miR-516b-5p/KPNA4-dependent manner.Journal of orthopaedic surgery and research · 2021Article
- hsa_circ_0000006 induces tumorigenesis through miR-361-3p targeting immunoglobulin-like domains protein 1 (LRIG1) in osteosarcoma.Annals of translational medicine · 2021Article
- CircPRDM2 Contributes to Doxorubicin Resistance of Osteosarcoma by Elevating EZH2 via Sponging miR-760.Cancer management and research · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThe purpose of this study was to detect the expression level of circRNA hsa_circ_0003074 in the tissues and peripheral blood of patients with osteosarcoma, and to explore its value in diagnosis and predicting prognosis of patients with osteosarcoma. MATERIALS AND
methodsTissue samples of osteosarcoma patients for chip sequencing were collected and circRNA hsa_circ_0003074, which was associated with the most obvious differential expression, was selected for qRT-PCR analysis. At the same time, the expression levels of hsa_circ_0003074 in different osteosarcoma cell lines, and in the peripheral blood of osteosarcoma patients before and after chemotherapy or surgery, as well as those in healthy volunteers matched by age and sex were also tested. This study aimed to explore the relationship between hsa_circ_0003074 and clinical characteristics of patients with osteosarcoma and analyzed its impact on patient survival.
resultsHigh expression of hsa_circ_0003074 was detected in osteosarcoma tissues, peripheral blood and osteosarcoma cell lines, and the expression level of hsa_circ_0003074 in the peripheral blood of patients with osteosarcoma decreased significantly after chemotherapy or surgery. In addition, hsa_circ_0003074 was closely related to clinical characteristics, such as tumor size, lung metastasis, enneking stage, and chemotherapy resistance. The ROC curve showed that hsa_circ_0003074 was a good diagnostic indicator for osteosarcoma, and survival analysis results revealed that high expression of hsa_circ_0003074 affected the survival of patients.
conclusionhsa_circ_0003074 is not only highly expressed in the tissues and peripheral blood of osteosarcoma patients but also a reliable diagnostic and prognostic biomarker for osteosarcoma patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.